Business Wire

JDI

23.8.2024 09:01:29 CEST | Business Wire | Press release

Share
JDI Develops World's First Automotive Grade Dual Touch 2 Vision Display (2VD)

This press release is intended to redistribute the content that was already disclosed on August 2, 2024, for an international audience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240823676155/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

2 Vision Display (Graphic: Business Wire)

JDI has developed the world's first 2 Vision Display (2VD) technology that meets automotive grade image quality requirements while simultaneously displaying different image content based on viewing direction. As another world's first, JDI has incorporated Dual Touch into its new 2VD technology that identifies discrete touch operations from different users. JDI Dual Touch 2VD thus enables a single display to function as two separate touch-enabled displays.

2VD has existed as a concept for many years. Unfortunately, it has historically been unable to overcome image quality issues to achieve commercialization and product use.

With its new Dual Touch 2VD technology, JDI has deployed its world-leading LTPS and optics capabilities to generate the necessary breakthrough in image quality to allow for widespread use. As an automotive use case, JDI Dual Touch 2VD simultaneously provides a large-screen, rich-content information display to the driver to support safe driving and a large-screen, high-quality passenger display on a single display. Dual Touch 2VD also resolves interior design constraints caused by the increase in displays, while allowing the reduction of in-car display usage to support streamlined and sophisticated interior designs.

2VD has also historically lacked touch functionality, an important capability for many use cases. JDI Dual Touch 2VD uses JDI-developed custom ICs to identify whether touch operations originate from the driver or passenger (again, using an automotive use case example), allowing a single display to function as two separate touch-enabled displays.

JDI is currently in discussions with multiple global automobile OEMs to incorporate JDI Dual Touch 2VD into their next-generation vehicle interiors, with first shipment possible as early as 2025. In collaboration with these OEMs, JDI is working to create unprecedented levels of automobile safety and comfort.

Existing 2VD vs. New JDI Dual Touch 2VD

 

 Existing 2VD

New JDI

Dual Touch 2VD

Resolution

88 ppi

171 ppi

Brightness

350 nits

700 nits

Contrast

350 : 1

1000 : 1

NTSC Ratio

70%

85%

Touch Functionality

None

Dual Touch

Furthermore, JDI Dual Touch 2VD’s rich functionality goes beyond the automotive industry. It has a broad set of use cases in an extraordinarily rich variety of contexts, locations, and industries and in both horizontal and vertical 2VD modes. As examples, JDI Dual Touch 2VD can be deployed in large signage applications or to create display security and privacy enhancements through viewing angle control, or to support innovative gaming applications.

A sample vertical use case of JDI Dual Touch 2VD would be a large display at a transportation hub such as an airport or train station, in which the changing user viewing angle, depending on the distance between the display and the user, allows for the simultaneous provision of rich visuals, art or other creative content, general information, or advertising (at a distance) and departure/arrival information (up close).

JDI Dual Touch 2VD is a breakthrough display technology that has the potential to change the way displays are used – and shared – all over the world in fundamentally new ways. JDI looks forward to open innovation and collaboration with individuals, organizations, and creative communities globally to explore new use cases for JDI Dual Touch 2VD that enrich people’s daily lives. Please feel free to contact us at:
https://www.webcoms.jp/jdi/eng/form.php?pid=524

2 Vision Display presentation video
https://youtu.be/zBnz1GirUYE

[Provisional Translation Only]
This translation is provided solely for information purposes.
Should there be any discrepancies between this translation and the Japanese original, the latter shall prevail.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240823676155/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye